US 12,064,439 B2
Phenothiazine diaminium salts and their use
Colin Marshall, Old Aberdeen (GB); Scott Clunas, Aberdeenshire (GB); John Mervyn David Storey, Aberdeenshire (GB); James Peter Sinclair, Aberdeenshire (GB); Thomas Craven Baddeley, Old Aberdeen (GB); Ahtsham Ishaq, Aberdeenshire (GB); Michael Simpson, Aberdeenshire (GB); Craig Williamson, Guildford (GB); Barry Alan Wood, Aberdeenshire (GB); Claude Michel Wischik, Aberdeen (GB); Charles Robert Harrington, Aberdeenshire (GB); Janet Elizabeth Rickard, Aberdeenshire (GB); David Horsley, Aberdeenshire (GB); Yin Sze Loh, Singapore (SG); Karrar Ahmad Khan, West Bridgeford (GB); and Christopher Paul Larch, Aberdeenshire (GB)
Assigned to WisTa Laboratories Ltd., Singapore (SG)
Filed by WisTa Laboratories Ltd., Singapore (SG)
Filed on Oct. 12, 2021, as Appl. No. 17/499,498.
Application 16/751,811 is a division of application No. 15/912,166, filed on Mar. 5, 2018, granted, now 10,864,216.
Application 15/912,166 is a division of application No. 15/056,610, filed on Feb. 29, 2016, granted, now 9,907,804, issued on Mar. 16, 2018.
Application 15/056,610 is a division of application No. 13/984,841, granted, now 9,283,230, previously published as PCT/GB2011/001221, filed on Aug. 15, 2011.
Application 17/499,498 is a continuation of application No. 16/751,811, filed on Jan. 24, 2020, granted, now 11,180,464, issued on Nov. 23, 2021.
Claims priority of provisional application 61/485,880, filed on May 13, 2011.
Claims priority of application No. 201101060-0 (SG), filed on Feb. 11, 2011.
Prior Publication US 2022/0098161 A1, Mar. 31, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5415 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61P 31/04 (2006.01); A61P 31/12 (2006.01); A61P 31/14 (2006.01); A61P 31/18 (2006.01); A61P 33/02 (2006.01); A61P 33/06 (2006.01); A61P 35/00 (2006.01); C07D 279/20 (2006.01); A61K 9/28 (2006.01); A61L 2/00 (2006.01); C07C 303/32 (2006.01); C07C 309/04 (2006.01); C07C 309/05 (2006.01); C07C 309/30 (2006.01); C07C 309/35 (2006.01)
CPC A61K 31/5415 (2013.01) [A61K 9/0053 (2013.01); A61K 9/2095 (2013.01); A61P 31/04 (2018.01); A61P 31/12 (2018.01); A61P 31/14 (2018.01); A61P 31/18 (2018.01); A61P 33/02 (2018.01); A61P 33/06 (2018.01); A61P 35/00 (2018.01); C07D 279/20 (2013.01); A61K 9/2893 (2013.01); A61L 2/0052 (2013.01); C07C 303/32 (2013.01); C07C 309/04 (2013.01); C07C 309/05 (2013.01); C07C 309/30 (2013.01); C07C 309/35 (2013.01); Y02A 50/30 (2018.01)] 18 Claims
OG exemplary drawing
 
1. A dosage unit comprising 20 to 300 mg of a compound of the following formula:

OG Complex Work Unit Chemistry
or comprising 20 to 300 mg of a free base equivalent of said compound, and further comprising a pharmaceutically acceptable carrier, diluent, or excipient.